2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Drug-Drug Interactions, Supportive Care, Biological Therapies, Transfusion, Non-Biological Therapies, Pharmacology, Women’s Health, Adverse Events, Biological Processes, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality Improvement, Quality of Care, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Platelet Disorders, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, Infectious Diseases, Metabolic Disorders, Iron Deficiency, Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Pregnant, Young Adult
PAPER

2701 Patterns of varicella zoster virus (VZV) infection in patients with hematologic malignancies: Clinical features, vaccination status, and antiviral prophylaxis

Rich Kodama, Judy Yan, PhD2, Eytan M Stein I, MD3, Miguel-Angel Perales, MD4, Gilles Salles I, MD, PhD5, Saad Z. Usmani, MD6, Mini Kamboj7, Zainab Shahid, MBBS8
1 Memorial Sloan Kettering Cancer Center, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York, United States
3 Memorial Sloan Kettering Cancer Center, New York, United States
4 Memorial Sloan Kettering Cancer Center, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York, United States

Background: Routine acyclovir prophylaxis is effective against varicella zoster virus (VZV) reactivation in patients with hematological malignancies (HM). Still, herpes zoster poses a significant risk after prophylaxis discontinuation and in those with poor adherence to daily antiviral. The availability of an effective and safe vaccine, recombinant zoster vaccine (RZV), provides an additional layer of protection but the uptake in HM patients remains low. We report on the burden and severity of herpes zoster (HZ) in HM patients, with a focus on severity, antiviral prophylaxis, and prior RZV receipt.

Methods: We retrospectively reviewed patients with an HM and PCR confirmed VZV infection (skin, CSF, blood) identified between January 2018 and November 2025, under an IRB approved protocol. Demographics, malignancy type, transplant/CAR T cell history, RZV vaccination status, antiviral prophylaxis and episode characteristics were collected by chart review. Complicated VZV infection was the primary outcome, and defined as disseminated cutaneous zoster, zoster ophthalmicus, and VZV meningoencephalitis. Secondary outcomes were VZV associated hospitalization, anti-viral prophylaxis use, and the association of RZV receipt on disease severity. Univariate logistic regression assessed candidate risk factors and severity outcomes. Statistical analyses were carried out using SAS 9.4 (SAS Institute, Cary, NC, USA). All P values less than 0.05 were considered statistically significant.

Results: Overall, 115 HM patients with HZ episodes were identified. Median age was 62 years (IQR 49–74), and 50.4% (58/115) were men. Lymphoid malignancy was the most common underlying disease (68/115,59%) followed by plasma cell dyscrasia (23/115,20%) and myeloid disorders (22/115,19%). Thirty-one patients (27%) had a history of HCT or CAR T cell therapy, at a median time of 2.6 years (IQR 1.3-5.0) before VZV diagnosis. Systemic anticancer therapy within 30 days of HZ was 49 (43%) and 48 patients (42%) received systemic corticosteroids.  Absolute neutrophil count (ANC) and absolute lymphocyte count (ALC) values immediately prior to VZV diagnosis were available for 108 patients where the median ANC was 3.4 ×10^9/L (2.1–5.7) and ALC was 1.0×10^9/L (0.6–2.3) (n=85).   
Prior RZV was documented in 24 patients (20.9%, 19 two doses, 5 one dose), a median of 437 days (IQR 281-986) before reactivation. Only 18 patients (15.7%) were on acyclovir prophylaxis within 30 days of HZ onset. Regrading severity, 32% of infections were complicated, including 21 (8.3%) patients with disseminated cutaneous zoster, 8 (22.2%) with zoster ophthalmicus and 7 (19.4%) with VZV meningoencephalitis. Infection-related hospitalizations occurred in 48 patients (41.7%).

In univariable analysis, plasma cell disorders were associated with a higher odd of complicated infection (OR 3.45, 95% CI 1.32–9.00; p=0.011) as was acyclovir prophylaxis within 30 days (OR 6.08, 95% CI 2.06–18.0; p=0.001), a finding likely due to confounding by host factors. Prior RZV vaccination was not protective against complicated infection (OR 1.79, 95% CI 0.70–4.53; p=0.222).  Age, sex, prior HCT/CAR T cell therapy, recent systemic therapy, corticosteroid exposure, IVIG, recent COVID-19 vaccination, lymphopenia and neutropenia were not associated with severity. Additional analyses are underway.

Conclusion: Despite the availability of prophylaxis and vaccine, HZ poses a substantial disease burden. Nearly one third of HZ episodes in patients with HM were complicated and over 40% led to hospitalization, Plasma cell disorders carried the highest odds of complicated disease. Vaccine uptake was low and unreliable for an effectiveness analysis.  Larger comparative studies are needed to define which HM patients would benefit from vaccination and extended antiviral prophylaxis.

Rich Kodama: No relevant conflicts of interest to declare.